Clinical and Microbiological Effects of Surgical Access Combined With Systematically Administered Antibiotics in the Treatment of Peri-implantitis: 1-year Randomized Double-blinded Controlled Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 89
- 试验地点
- 1
- 主要终点
- Difference between treatment groups for the change in the clinical attachment level (CAL).
研究概览
简要总结
This randomized clinical trial evaluates the clinical and microbiological (microbial complexes and changes in the diversity of the submucosal biofilm) effects of MTZ+AMX as adjuncts to anti-infectious surgical treatment plus Er: YAG in the treatment of peri-implantitis.
详细描述
Peri-implantitis is a pathological condition characterized by inflammation of peri-implant connective tissues and progressive peri-implant bone. Recently, the therapeutic protocol using non-surgical debridement associated with the combination of systemic metronidazole (MTZ) and amoxicillin (AMX) has not been shown to be effective in controlling the disease. These unfavorable results may have occurred due to the limitation in the change of the submucosal microbiological profile due to mechanical difficulties in the decontamination of the implant threads. Therefore, this randomized clinical trial (RCT) aimed to evaluate the clinical and microbiological (microbial complexes and changes in the diversity of the submucosal biofilm) effects of MTZ+AMX as adjuncts to anti-infectious surgical treatment plus Er:YAG in the treatment of peri-implantitis. Ninety-four subjects with untreated peri-implantitis are being included and will be randomly assigned to receive (i) open flap debridement plus Er:YAG irradiation alone (control), or (ii) with adjunctive systemically administered MTZ (400 mg) + AMX (500 mg) thrice a day (TID) for 14 days (test). Subjects will be monitored up to 12 months post-treatment. Submucosal biofilm samples from the deepest site of each implant with peri-implantitis will be collected in duplicate per patient: at baseline and at 3, 6 and 12 months post-therapy and analyzed by checkerboard DNA-DNA hybridization for 40 bacterial species, and at baseline, 3 and 12 months post-treatment for 16S rRNA sequencing (Ion Torrent PGM System). The primary outcome variable of this trial will be the difference between treatment groups for the change in CAL from baseline to 12 months. The significance of differences in each group (over the course of the study) will be sought using the Student's-t test; and among groups (at each time point) using either ANOVA /ANCOVA or Kruskal Wallis tests and post-hoc analyses, depending on normality of the data. Fisher's exact test will be used to compare differences in the frequency of gender. Statistical significance will be set at 5%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-70 years of age;
- •in general good health,
- •at least one dental implant in function for at least one year with untreated peri-implantitis defined as: presence of bleeding and/or suppuration on gentle probing, probing depths (PD) ≥ 6mm, and bone levels ≥3mm apical of the most coronal portion of the intraosseous part of the implant.
排除标准
- •subjects with ≥6 sites with PD ≥5mm;
- •individuals that received periodontal treatment within three months prior to entering the study;
- •inability to perform proper supramucosal and supragingival plaque control (e.g., due to improper restoration design or lack of skills);
- •poorly adapted implant-supported restoration;
- •diabetes;
- •pregnancy;
- •history of allergies to metronidazole and/or amoxicillin, or any other ingredient of oral care products;
- •alcohol or drug abuse;
- •any systemic diseases that could affect post-operative healing or that required antibiotic premedication for routine dental therapy;
- •long-term use of mouthrinses;
- •anti-inflammatory medications;
- •any other drug that could interfere with the study outcomes within three months prior to entering the study;
- •use of antibiotics within six months prior to entering the study.
研究组 & 干预措施
Control
Open flap debridement + Er: YAG irradiation alone + systemic placebo of metronidazole and amoxicillin thrice a day (TID) for 14 days
干预措施: Open flap debridement (Procedure)
Control
Open flap debridement + Er: YAG irradiation alone + systemic placebo of metronidazole and amoxicillin thrice a day (TID) for 14 days
干预措施: Placebos (Drug)
Test
Open flap debridement + Er: YAG irradiation alone + systemic metronidazole (400mg) and amoxicillin (500mg) thrice a day (TID) for 14 days
干预措施: Open flap debridement (Procedure)
Test
Open flap debridement + Er: YAG irradiation alone + systemic metronidazole (400mg) and amoxicillin (500mg) thrice a day (TID) for 14 days
干预措施: Metronidazole (Drug)
Test
Open flap debridement + Er: YAG irradiation alone + systemic metronidazole (400mg) and amoxicillin (500mg) thrice a day (TID) for 14 days
干预措施: Amoxicillin (Drug)
结局指标
主要结局
Difference between treatment groups for the change in the clinical attachment level (CAL).
时间窗: 12 months.
次要结局
- Percentage of patients (and implants) reaching the following clinical endpoint for treatment: PD< 5mm, absence of BOP and no further bone loss.(12 months.)
- Mean plaque index.(Baseline, 3, 6 and 12 months.)
- Mean gingival index.(Baseline, 3, 6 and 12 months.)
- Percentage of sites with bleeding on probing.(Baseline, 3, 6 and 12 months.)
- Percentage of sites with suppuration.(Baseline, 3, 6 and 12 months.)
- Probing depth.(Baseline, 3, 6 and 12 months.)
- Occurrence of headache obtained through a questionnaire of adverse effects.(14 days after taking antibiotic.)
- Occurrence of vomiting obtained through a questionnaire of adverse effects.(14 days after taking antibiotic.)
- Occurrence of diarrhea obtained through a questionnaire of adverse effects.(14 days after taking antibiotic.)
- Occurrence of metallic taste obtained through a questionnaire of adverse effects.(14 days after taking antibiotic.)
- Occurrence of nausea obtained through a questionnaire of adverse effects.(14 days after taking antibiotic.)
- Occurrence of irritability obtained through a questionnaire of adverse effects.(14 days after taking antibiotic.)
- Counts of periodontal pathogenic bacterial species.(Baseline, 3, 6 and 12 months.)
- Proportions of periodontal pathogenic bacterial species.(Baseline, 3, 6 and 12 months.)
研究者
Jamil awad shibli
Professor
University of Guarulhos